Latest database descriptions

Describe the prophylactic treatment of phlebitis in patients suffering from multiple myeloma and receiving thalidomide or lenalidomide treatment:
- Describe the proportion of patients under prophylactic treatment for phlebitis;
- Define the importance of low-molecular-weight heparins (LMWH), vitamin K antagonists (VKA) and aspirin, as well as the arrangements for their use in preventing phlebitis.

Describe, over a period of 4 and then 8 months, the occurrence of thromboembolic and hemorrhagic events in patients with multiple myeloma who are under thalidomide or lenalidomide treatment, depending on the thromboprophylactic strategy set up upon inclusion

Primary objective: determine the incidence of clinical vertebral fractures and non-vertebral fragility fractures in patients treated with teriparatide for about 18 months and a post-treatment follow-up period of at least 18 months.
Secondary objectives: observance, treatment switching and cessation, clinical evolution, occurrence of back pain, direct costs linked to fractures.

Primary objective: long-term follow-up of the clinical change and of the tolerance in patients with a somatotrope deficiency whether or not treated with somatropin (Umatrope®)

Primary objective: evaluate the overall survival of patients with a diagnosis of locally advanced or metastatic non-small cell lung cancer (stage IIIb or IV) initiating first-line chemotherapy combined with a platinum salt, whether or not combined with a targeted agent, in a daily practice setting.
Secondary objectives:
- Survival at 1 year, survival without progression and tumor response: according to histological subgroup and whether or not a target edagent is used;
- Diagnosis of histopathological/cytopathological subtype;
- Care pathway and use of resources.